We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Increased HbA1c Identifies Rapid Kidney Function Deterioration in Diabetics

By LabMedica International staff writers
Posted on 13 Nov 2019
Print article
Image: Diabetes and higher HbA1c levels are independently associated with adverse renal outcomes in inpatients following multiple hospital admissions (Photo courtesy of Anitha Anchan).
Image: Diabetes and higher HbA1c levels are independently associated with adverse renal outcomes in inpatients following multiple hospital admissions (Photo courtesy of Anitha Anchan).
Among adults with multiple hospital admissions, those with type 2 diabetes were more likely to have worsening renal function compared with those without diabetes. The association between glycemic status prior to the first hospital presentation with developing adverse renal outcomes overtime in patients with multiple hospital re-admissions has been assessed.

While poor glycemic control defined by higher HbA1c levels is associated with worse renal outcomes, the presence of diabetes independent of glycemic status is also associated with high risk of relatively rapid deterioration in renal function. Therefore, all patients with diabetes, regardless of their glycemic control, are a logical target for structured preventive interventions.

A team of scientists from the University of Melbourne (Melbourne, Australia) conducted a prospective observational cohort study with 4,126 adults aged at least 54 years who made two or more visits to Austin Hospital (Heidelberg, Australia) from 2013 to 2016 (median age, approximately 77 years; 41% women). Participants had estimated glomerular filtration rates of more than 30 mL/min/1.73 m2 and “no prior history of renal replacement therapy” before study onset. The team analyzed data on HbA1c and eGFR from 465 days of median follow-up time.

Diabetes was diagnosed in 26% of the population and the scientists noted that stage 4 chronic kidney disease developed in 19% of those with diabetes and 13% of those without diabetes. Among adults with multiple hospital admissions, those with type 2 diabetes were more likely to have worsening renal function compared with those without diabetes.

An eGFR decrease of more than 50% was more likely to occur for participants with diabetes versus without diabetes. The team also noted a higher predicted adjusted probability for those with diabetes and an eGFR of at least 45 mL/min/1.73 m2 before study onset. A “rapid decline in renal function,” which was characterized by an annual decrease in eGFR of more than 5 mL/min/1.73 m2, was more likely to occur for participants with versus without diabetes particularly between the first and second year of follow-up.

Ending the study at an eGFR of 30 mL/min/1.73 m2 was more likely for participants with diabetes compared with those without diabetes. The scientists noted that HbA1c at study onset did not affect the likelihood of ending at an eGFR of 30 mL/min/1.73 m2, but that it became 7% more likely that a 50% eGFR decrease would occur and 11% more likely that a “rapid decline” would occur with each HbA1c increase of 1% at baseline.

Niloufar Torkamani, MD, PhD, FRACP, an endocrinology/general medicine physician and lead author of the study, said, “We found that the presence of diabetes and higher HbA1c levels were strongly and independently associated with adverse renal outcomes at follow-up. Such patients are at high risk of relatively rapid deterioration in renal function and are a logical target for structured preventive interventions.” The study was published on October 22, 2019 in the Journal of Diabetes and its Complications.

Related Links:
University of Melbourne
Austin Hospital


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.